Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M109,391Revenue $M18,676Net Margin (%)25.7Z-Score2.4
Enterprise Value $M116,531EPS $6.6Operating Margin %31.6F-Score4
P/E(ttm))22.1Cash Flow Per Share $6.7Pre-tax Margin (%)28.2Higher ROA y-yN
Price/Book4.510-y EBITDA Growth Rate %11.0Quick Ratio4.0Cash flow > EarningsY
Price/Sales5.75-y EBITDA Growth Rate %8.7Current Ratio4.4Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %20.5ROA % (ttm)8.0Higher Current Ratio y-yN
Dividend Yield %1.6Insider Buy (3m)1ROE % (ttm)22.5Less Shares Outstanding y-yN
Payout Ratio %33.0Shares Outstanding M757ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNDaniel Loeb 2014-06-30 Buy 0.65%$110.29 - $126.07
($115.72)
$ 144.1725%New holding, 450000 sh.450,000
AMGNJoel Greenblatt 2014-06-30 Buy 0.02%$110.29 - $126.07
($115.72)
$ 144.1725%New holding, 9938 sh.9,938
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 144.1725%Add 85.28%60,335
AMGNJohn Hussman 2014-06-30 Reduce-0.93%$110.29 - $126.07
($115.72)
$ 144.1725%Reduce -66.67%50,000
AMGNMario Gabelli 2014-03-31 Add0.01%$113.48 - $127.47
($121.04)
$ 144.1719%Add 37.87%32,565
AMGNDodge & Cox 2014-03-31 Reduce$113.48 - $127.47
($121.04)
$ 144.1719%Reduce -22.59%105,757
AMGNPRIMECAP Management 2014-03-31 Reduce-0.46%$113.48 - $127.47
($121.04)
$ 144.1719%Reduce -9.42%32,161,744
AMGNVanguard Health Care Fund 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 144.1719%Reduce -6.4%8,213,855
AMGNJohn Hussman 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 144.1719%Reduce -14.29%150,000
AMGNJoel Greenblatt 2014-03-31 Sold Out -0.06%$113.48 - $127.47
($121.04)
$ 144.1719%Sold Out0
AMGNRay Dalio 2014-03-31 Sold Out -0.01%$113.48 - $127.47
($121.04)
$ 144.1719%Sold Out0
AMGNJoel Greenblatt 2013-12-31 Buy 0.06%$106.28 - $118.688
($113.73)
$ 144.1727%New holding, 23170 sh.23,170
AMGNRay Dalio 2013-12-31 Buy 0.01%$106.28 - $118.688
($113.73)
$ 144.1727%New holding, 7513 sh.7,513
AMGNVanguard Health Care Fund 2013-12-31 Reduce-0.76%$106.28 - $118.688
($113.73)
$ 144.1727%Reduce -18.43%8,775,155
AMGNJohn Hussman 2013-12-31 Reduce-0.45%$106.28 - $118.688
($113.73)
$ 144.1727%Reduce -30%175,000
AMGNJohn Hussman 2013-09-30 Add0.3%$95.81 - $117.521
($108.55)
$ 144.1733%Add 25%250,000
AMGNMario Gabelli 2013-09-30 Add$95.81 - $117.521
($108.55)
$ 144.1733%Add 26.95%22,420
AMGNPRIMECAP Management 2013-09-30 Reduce-0.22%$95.81 - $117.521
($108.55)
$ 144.1733%Reduce -4.11%35,812,225
AMGNRay Dalio 2013-09-30 Sold Out -0.07%$95.81 - $117.521
($108.55)
$ 144.1733%Sold Out0
AMGNDodge & Cox 2013-09-30 Reduce-0.01%$95.81 - $117.521
($108.55)
$ 144.1733%Reduce -38.73%160,052
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AMGN Joel Greenblatt 2014-06-309,93800.02New Buy
AMGN Daniel Loeb 2014-06-30450,0000.060.65New Buy
AMGN Mario Gabelli 2014-06-3060,3350.010.04+85.28%
AMGN PRIMECAP Management 2014-06-3031,853,8444.214.1-0.96%
AMGN Vanguard Health Care Fund 2014-06-308,049,4551.062.5-2%
AMGN Dodge & Cox 2014-06-3085,8570.010.01-18.82%
AMGN John Hussman 2014-06-3050,0000.010.45-66.67%
Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.9712.66view
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.2913.26view
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.8327.78view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.7728.99view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4530.53view
de Carbonnel FrancoisDirector 2014-03-06Sell1,000$126.6913.8view
HENDERSON REBECCA MDirector 2014-02-13Sell20,000$123.5316.71view
AMGEN INC10% Owner 2013-12-17Buy272,142$71959.57view
Balachandran MadhavanEVP, Operations 2013-09-04Sell18,000$112.7627.86view
BALTIMORE DAVIDDirector 2013-08-28Sell4,582$109.6631.47view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
    Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
    After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
    Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
    Amgen Inc: As Good as It Gets? Feb 20 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Mario Gabelli Comments on Amgen Inc. Jan 06 2014 
    The Gabelli Asset Fund Shareholder Commentary - Third Quarter Jan 06 2014 
    38 Stocks with Higher Dividends Dec 23 2013 
    Vanguard Health Care Fund’s Top Third Quarter Holdings Oct 31 2013 

    More From Our Partners
    VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog Sep 19 2014 - ZACKS

    More From Other Websites
    Today's Market Thorns, Roses, and All Time Highs... Sep 19 2014
    Today's Market Thorns, Roses and All Time Highs... Sep 18 2014
    UCB-Amgen Reveals Positive Data on Romosozumab for PMO Sep 17 2014
    The Market's Thorns, Roses, and All Time Highs... Sep 17 2014
    Amgen, Inc. Poised To Break Higher Sep 17 2014
    Biotech still place to be: Pro Sep 15 2014
    [video] Biotech still place to be: Pro Sep 15 2014
    Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of... Sep 15 2014
    New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued... Sep 15 2014
    Amgen Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure Sep 14 2014
    US STOCKS-Biotech shares drop, Amarin plunges 20 pct Sep 12 2014
    Medivation Eyes Blockbuster As Cancer Drug Gets An OK Sep 11 2014
    Short Sellers Remain Vigilant Against Biotechs Sep 11 2014
    [video] Marathon Oil, Amgen Smart Long Haul Stocks Says Forester Fund Manager Sep 10 2014
    Amgen, Inc. Showing More Upside Potential Sep 10 2014
    Amgen Announces 23 Abstracts To Be Presented At The American Society for Bone and Mineral Research... Sep 10 2014
    Five Reason Amgen Won't Be Breaking Up Sep 08 2014
    Amgen To Present At The Morgan Stanley Global Healthcare Conference Sep 05 2014
    Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Sep 04 2014
    Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Sep 03 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK